Shackelford Pharma Inc. Selected to
Present at Life Science BC Invest in BC
Vancouver BC, Canada (October 16,
2022) — Shackelford Pharma Inc., a pharmaceutical company developing medicines
for neurological diseases with significant unmet patient needs, is proud to be
selected to present at the upcoming “Life Sciences BC Invest in BC” Event. This
annual event is an opportunity to bring together stakeholders in the healthcare
innovation ecosystem. The two-day event includes company pitches,
presentations, and panel discussions, giving entrepreneurs a platform to share
their stories and receive feedback and engagement from a wide range of investor
stakeholders. Investor participants include angel investors, venture capital,
corporate venture, and foundations. Shackelford Pharma will be sharing our
unique story with this audience for the first time, as we look to establish our
presence in the biotech community and secure investment that will support our
growth as a pharmaceutical development company focused on the endocannabinoid
Inquires to the Company can be
made by calling us directly at 1-888-377-4225 Ext.1., or by emailing us at firstname.lastname@example.org.
Additional company information is
available on our website www.shackelfordpharma.com,
where you are also be able to sign up to receive updates from Shackelford
Pharma Inc. as we advance our clinical program.
Mark Godsy, CEO
Shackelford Pharma Inc.
Based upon Dr. Alan Shackelford’s real-world experience, Shackelford Pharma, Inc., was formed to develop medicines for neurological diseases with significant unmet patient needs. Members of Its world class R&D team collectively have over 320 years of drug development experience. This includes having developed 43 FDA approved drugs, 7 with peak annual revenue over $1B USD, and 6 anti-epileptic drugs. Shackelford’s first drug candidate, SP1707, is a small molecule, long-acting oral formulation targets a specific seizure type.
Please visit us at www.shackelfordpharma.com
This news release may contain both historical and forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. Some of the statements herein constitute forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and “would” or the negatives of these terms, or other comparable terminology. To the extent that this document contains forward-looking statements regarding our business, please be advised that our actual financial condition, operating results, and business performance may differ materially from that projected or estimated by us in forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.
Although the forward-looking statements in this document are based on our beliefs, assumptions, and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements, or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law, to re-issue this document or otherwise make public statements updating our forward-looking statements.
This news release does
not constitute an offer to sell or a solicitation of an offer to buy any
securities in the United States. In the United States under
the Securities Act of 1933, any offer to sell securities must
either be registered with the United States Securities and Exchange
Commission (SEC) or meet certain qualifications to exempt it from such
registration. An offering circular on Form 1-A was filed with the
Securities and Exchange Commission (“SEC”) and was qualified by the
SEC as of August 20, 2020. The offering of these securities was made only by
means of an offering circular on Form 1-A.